Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs ResMed Inc. — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.4× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and ResMed Inc. pays a 1.16% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and ResMed Inc. for 51 Days on average.
| JNK | RMD | |
|---|---|---|
Market Cap | $5.86B | $31.89B |
Volume | 7,780,002 | 618,314 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $277.88 |
52-Week Low | $92.30 | $182.82 |
Typical Hold Time | 61 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK, a high-yield bond ETF, trades at $92.83, up 0.08% on the day, amid a bearish technical signal from moving averages. The fund maintains a consistent dividend payout, with recent distributions of $0.53. Market sentiment is influenced by rising bond yields and geopolitical tensions, as highlighted in recent financial news.
The outlook for JNK is challenged by high interest rates and inflation concerns, which pressure junk bond valuations. Opportunities exist for income-focused investors due to the ETF's yield, but risks include further yield spikes and economic slowdowns affecting credit quality.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
